600594.CG▼
Yibai Pharmaceutical's 2026 interim report shows net loss of 80.34 million yuan, widening year-on-year
Yibai Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at a loss of 80.34 million yuan, an increase in loss of 60.44 million yuan compared with the same period last year. The company's total operating revenue was 689 million yuan, down 30.58% year-on-year; net cash inflow from operating activities was 64.14 million yuan, down 62.39% year-on-year. The company's latest asset-liability ratio was 32.90%, gross margin was 57.67%, ROE was -3.81%, and diluted earnings per share was -0.10 yuan.
Jiemian·5dRead more ▾
600594.CG▼
Yibai Pharmaceutical posts first-half net loss of about 80.34 million yuan
Yibai Pharmaceutical released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 80.34 million yuan in the first half, compared with a loss of about 19.9 million yuan in the same period last year. The company achieved operating revenue of about 689 million yuan in the first half, down 30.58 percent year on year. Yibai Pharmaceutical said the loss was mainly due to a decline in sales of major products, while costs and expenses still exceeded revenue.
北京商报·6dRead more ▾
600594.CG▼
Yibai Pharmaceutical faces 700,000 yuan fine over children's cough syrup violations, with cumulative losses exceeding 700 million yuan over two and a half years
Yibai Pharmaceutical announced that the Guizhou Medical Products Administration intends to fine it 700,000 yuan for failing to comply with Good Manufacturing Practice for Drugs during the production of children's cough syrup. The penalty stems from inspections that uncovered issues such as non-standard excipient testing and inconsistent disinfection records. The company had its production and sale of this drug suspended in August 2025, resuming in September after rectification. Earlier, in April 2024, its core product Aidi injection was fined over 8.2 million yuan and had production halted for similar violations, and it has yet to resume production. Financial data shows that in 2024, 2025, and the first half of 2026, the company's net profit attributable to shareholders was negative 317 million yuan, negative 330 million yuan, and an estimated loss of 74 million to 88.8 million yuan, respectively, with cumulative losses exceeding 700 million yuan over two and a half years. Meanwhile, the company's research and development expenses declined for five consecutive years, from 136 million yuan in 2021 to 84 million yuan in 2025.
经济参考网·17dRead more ▾
Yibai Pharmaceutical Fined 700,000 Yuan for Violating Drug Manufacturing Quality Standards
Yibai Pharmaceutical announced that it has received an administrative penalty notice from the Guizhou Medical Products Administration, imposing a fine of 700,000 yuan for suspected failure to comply with drug manufacturing quality management standards. An investigation found multiple issues, including 27 batches of sucrose and one batch of vanillin excipient not being tested according to procedures upon incoming inspection, inconsistent disinfection time records for the purified water preparation system, and the absence of paper cleaning operation records for the pediatric cough syrup dispensing system. The company stated that this penalty is a follow-up administrative action to the previously disclosed suspension and rectification of pediatric cough syrup production in 2025. After rectification, production and sales of the product resumed in September 2025, and this administrative penalty does not involve any new violations.
北京商报·27dRead more ▾
600594.CG▲
Guizhou Listed Companies Report Strong First-Half Earnings Forecasts, Cash Dividends and Buybacks Rank First in Western China
Recently, Guizhou listed companies have been intensively disclosing their first-half 2026 earnings forecasts, with many delivering impressive results. CNGR Advanced Material expects a net profit attributable to shareholders of 1.25 billion to 1.35 billion yuan, up 70.58% to 84.23% year-on-year, with core product sales exceeding 250,000 tonnes. Qian Yuan Power expects net profit to rise over 70% year-on-year. Anda Technologies, Panjiang Coal and Electric Power, and Chitianhua all turned losses into profits. At the same time, Guizhou listed companies are actively rewarding investors. Since the beginning of this year, cumulative cash dividends have reached 38.378 billion yuan, and share buybacks have totalled 3.387 billion yuan, both ranking first in the western region. The chairman of Qian Yuan Power has proposed a 2026 interim dividend, and companies including Kweichow Moutai, Guizhou Gas, and Vontron Technology have already made clear plans. In addition, Yibai Pharmaceutical and Guizhou Bailing recently disclosed that they will change the purpose of their share buybacks to cancellation and reduction of registered capital, while Chanhen Chemical completed the cancellation of 1.76 million repurchased shares in March this year.
央广财经·29dRead more ▾
600594.CG▼
Yibai Pharmaceutical expects first-half net loss of 74 million to 88.8 million yuan, widening year-on-year
Yibai Pharmaceutical has released its 2026 half-year performance forecast, expecting a net loss attributable to shareholders of 74 million to 88.8 million yuan, compared with a loss of 19.9021 million yuan in the same period last year, widening the loss year-on-year. The company said that during the reporting period, sales of its main products declined, leading to an expected 30 percent drop in revenue. Although costs and expenses are expected to fall by 26 percent, they still exceed revenue, resulting in the loss.
北京商报·44dRead more ▾
600594.CG▲
Multiple A-share Companies Announce Buybacks and Stake Increases; Neusoft Plans Buyback with Full Cancellation
On the evening of July 9, multiple A-share listed companies issued announcements on share buybacks and stake increases. Neusoft announced that, because its stock price is below net asset value per share, it plans to buy back shares worth 100 million to 200 million yuan and cancel them all. Based on a maximum buyback price of 11.67 yuan per share, the number of shares to be repurchased is approximately 8.57 million to 17.14 million, accounting for 0.72% to 1.43% of total share capital. Yibai Pharmaceutical will cancel 7.53 million repurchased shares, representing 0.95% of total share capital, after which total share capital will change to 784 million shares. Unigroup Guoxin will cancel 6.40 million shares because the repurchased shares were not used for an incentive plan within 36 months. Sansure Biotech will cancel 4.45 million shares to reduce registered capital, aiming to boost earnings per share. Chongqing Pharmaceutical has completed the cancellation procedures for 15.41 million repurchased shares. Dazhong Mining made its first buyback of 580,000 shares, with a transaction amount of 17.51 million yuan. Jiayi Holdings made its first buyback of 64,200 shares, with a transaction amount of 1.99 million yuan. Qingmu Technology plans to buy back shares worth 20 million to 30 million yuan for incentive purposes. On the stake increase side, Sheng Jianhua, one of the actual controllers of Xidian New Energy, increased his stake by 614,900 shares, with an amount of 19.45 million yuan. Actual controllers Sheng Jianhua and Pan Shuxin plan to increase their combined stake by 10 million to 20 million yuan. The controlling shareholder of Shenghang Shipping, Wanda Holding Group, plans to increase its stake by no more than 6.10 million shares, with an amount of 66 million to 96 million yuan. Liu Xiaodong, the actual controller of Bairun Holdings, increased his stake by 1.12 million shares, with an amount of 17.98 million yuan, and plans to continue increasing his stake by 50 million to 100 million yuan. Some directors and senior executives of Longxi Bearing increased their combined stake by 67,400 shares, with an amount of 909,400 yuan.
证券时报·49dRead more ▾